Abstract: An integrated sheet structure for a secondary battery, including a first mixture layer containing a first active material and a first binder, a second mixture layer containing a second active material and a second binder, and a third mixture layer located between the first mixture layer and the second mixture layer and containing solid particles and a third binder, in which the first mixture layer and the third mixture layer are bonded each other, and the second mixture layer and the third mixture layer are bonded each other.

Abstract: Provided is a secondary battery including a negative electrode, a positive electrode, a separation layer in contact with an active material-containing layer of the negative electrode, and an aqueous electrolyte. A first concentration corresponding to a first metal concentration represented by Equation 1 (first metal concentration=atomic concentration of Hg, Pb, Zn, and/or Bi/sum of atomic concentrations of elements B to U in periodic table, excluding carbon and oxygen) in a boundary region between the active material-containing layer and the separation layer is 2% or more and 8.2% or less. A ratio of the first concentration to a second concentration corresponding to the first metal concentration represented by Equation 1 in the active material-containing layer excluding the boundary region is 2.5 or more and less than 4.

Abstract: It is intended to provide a compound inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same as one of the amino acid sequences represented by SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and so on, or its salt; a compound inhibiting the expression of a gene of the above protein; an antisense nucleotide containing a base sequence which is complementary or substantially complementary to the base sequence of a DNA encoding the above protein or its partial peptide or a part of the base sequence; an antibody against the above protein or its partial peptide; and so on. The above compound, antisense nucleotide, antibody and so on are usable as a prophylactic/therapeutic agent for respiratory diseases, etc.

Abstract: A novel sodium-dependent bile acid transporter protein, an Na+/H+ exchange transporter protein, a P-type ATPase protein and a vanilloid receptor protein, and polynucleotides encoding these proteins are useful in screening preventives/remedies for hyperlipemia, arteriosclerosis, genital diseases or digestive diseases; respiratory diseases, renal diseases or digestive diseases; pancreatic diseases, central nerve diseases, digestive diseases or respiratory diseases; inflammatory diseases, rheumatoid diseases or diabetic neurosis; etc.

Abstract: A novel sodium-dependent bile acid transporter protein, an Na+/H+ exchange transporter protein, a P-type ATPase protein and a vanilloid receptor protein, and polynucleotides encoding these proteins are useful in screening preventives/remedies for hyperlipemia, arteriosclerosis, genital diseases or digestive diseases; respiratory diseases, renal diseases or digestive diseases; pancreatic diseases, central nerve diseases, digestive diseases or respiratory diseases; inflammatory diseases, rheumatoid diseases or diabetic neurosis; etc.

Abstract: Novel proteins of the present invention that have an organic anion transport activity are useful as, for example, a diagnostic marker for kidney diseases, liver diseases, pancreas diseases, immunological diseases associated with thymus failures, reproductive diseases, digestive diseases, spleen diseases, cancer, respiratory diseases, myelitis, diabetes, hypertension, reperfusion injury following ischemia, retinitis, central nervous diseases, skin diseases, thyroid hormone-associated diseases, etc. Compounds that promote or inhibit the activity of the above protein, which are obtained by a screening method using the protein, can be used as, for example, prophylactic/therapeutic agents for the above-described diseases.

Abstract: It is intended to provide a compound inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same as one of the amino acid sequences represented by SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and so on, or its salt; a compound inhibiting the expression of a gene of the above protein; an antisense nucleotide containing a base sequence which is complementary or substantially complementary to the base sequence of a DNA encoding the above protein or its partial peptide or a part of the base sequence; an antibody against the above protein or its partial peptide; and so on. The above compound, antisense nucleotide, antibody and so on are usable as a prophylactic/therapeutic agent for respiratory diseases, etc.

Abstract: A novel sodium-dependent bile acid transporter protein, an Na+/H+ exchange transporter protein, a P-type ATPase protein and a vanilloid receptor protein, and polynucleotides encoding these proteins are useful in screening preventives/remedies for hyperlipemia, arteriosclerosis, genital diseases or digestive diseases; respiratory diseases, renal diseases or digestive diseases; pancreatic diseases, central nerve diseases, digestive diseases or respiratory diseases; inflammatory diseases, rheumatoid diseases or diabetic neurosis; etc.

Abstract: Novel proteins of the present invention that have an organic anion transport activity are useful as, for example, a diagnostic marker for kidney diseases, liver diseases, pancreas diseases, immunological diseases associated with thymus failures, reproductive diseases, digestive diseases, spleen diseases, cancer, respiratory diseases, myelitis, diabetes, hypertension, reperfusion injury following ischemia, retinitis, central nervous diseases, skin diseases, thyroid hormone-associated diseases, etc. Compounds that promote or inhibit the activity of the above protein, which are obtained by a screening method using the protein, can be used as, for example, prophylactic/therapeutic agents for the above-described diseases.

Abstract: Novel glucose transporter proteins, novel vesicular glutamate transporter proteins and a novel potential-dependent K+ channel protein, are useful as, for example, diagnostic markers, hyperlipemia, arteriosclerosis, etc. These proteins, compounds promoting or inhibiting the activities thereof, etc., which are obtained by a screening method with the use of these proteins, and so on, are usable as safe drugs for the prevention/treatment of the diseases above.

Abstract: A novel protein having a dicarboxylic acid transport activity, a DNA encoding this protein, a method of screening a compound that promotes or inhibits the activity of the protein, compounds obtained by the screening method, etc. are provided.